If the biotech titan that’s the focus of today’s article is going to improve its growth prospects, it may have to go acquisition shopping in the next few months – and one of the three companies that the author highlights could be its target, as he notes that all three are acquisitions that “the biotech could easily afford and that would dovetail nicely with its core areas of expertise.” For more on these three potential buyout targets, CLICK HERE.
